广西医学Issue(8)：1025-1027,3.DOI:10.11675/j.issn.0253-4304.2014.08.01
重组人血管内皮抑制素联合顺铂胸腔灌注治疗乳腺癌恶性胸腔积液的临床观察
Observation on Cavity Infusion Therapy with Recombinant Human Endostatin Combined with Cisplatin for Breast Cancer Patients with Malignant Pleural Effusion
摘要
Abstract
Objective To observe the effect and safety of the cavity infusion therapy with recombinant human endostatin ( Endostar ) combined with cisplatin for breast cancer with malignant pleural effusion .Methods The adequate drainage of pleural effusion was performed in 36 breast cancer patients with malignant pleural effusion by pleural central venous catheter implantation.And then saline+Endostar,saline+cisplatin,saline+dexamethasone were injected into the pleural cavity sequentially .Endostar was administered twice a week for three weeks ,while cisplatin and dexamethasone were used only twice a week in the first week.Results Of these 36 patients,CR of clinical evaluation was observed in 26 patients(72.2%),PR 5 patients(13.9%),SD 4 patients(11.1%),PD 1 patient(2.8%) and RR 31 patients(86.1%). There were 6 patients (16.7%) had mild pleural adhesions,thickening and separation.Twenty-nine patients (80.6%) gained an improvement of life quality ,6 patients(16.7%) maintained stability and 1 patient(2.8%) acquired lower life quality.The adverse reactions were nausea ,vomiting,chest pain,fever,neutropenia,with a low incidence of gradeⅠ-Ⅱ.Conclusion The cavity infusing Endostar combined with cisplatin is of good effect ,low adverse reactions and high security for the treatment of breast cancer with malignant pleural effusion .关键词
乳腺癌/恶性胸腔积液/重组人血管内皮抑制素/顺铂/药物疗法Key words
Breast cancer/Malignant pleural effusion/Recombinant human endostatin/Endostar/Cisplatin/Drug therapy分类
医药卫生引用本文复制引用
周文献,谢伟敏,陆永奎,刘燕,谭爱花,王洪学,农丽,贾昱娴..重组人血管内皮抑制素联合顺铂胸腔灌注治疗乳腺癌恶性胸腔积液的临床观察[J].广西医学,2014,(8):1025-1027,3.基金项目
广西医药卫生科研课题 （）
